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Abstract
Transforming growth factor-b (TGF-b) elicits both tumor-suppressive and tumor-promoting functions during cancer
progression. Here, we describe the tumor-promoting functions of TGF-b and how these functions play a role in cancer
progression. Normal epithelial cells undergo epithelial-mesenchymal transition (EMT) through the action of TGF-b, while
treatment with TGF-b and ﬁbroblast growth factor (FGF)-2 results in transdifferentiation into activated ﬁbroblastic cells that
are highly migratory, thereby facilitating cancer invasion and metastasis. TGF-b also induces EMT in tumor cells, which can be
regulated by oncogenic and anti-oncogenic signals. In addition to EMT promotion, invasion and metastasis of cancer are
facilitated by TGF-b through other mechanisms, such as regulation of cell survival, angiogenesis, and vascular integrity, and
interaction with the tumor microenvironment. TGF-b also plays a critical role in regulating the cancer-initiating properties of
certain types of cells, including glioma-initiating cells. These ﬁndings thus may be useful for establishing treatment strategies
for advanced cancer by inhibiting TGF-b signaling.
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Introduction
Transforming growth factor-b (TGF-b) is a multi-
functional regulator of cell growth, apoptosis, differ-
entiation, and migration. TGF-b1 was originally
discovered as a secreted protein that induces
anchorage-independent growth in normal rat kidney
NRK49F ﬁbroblasts in the presence of epidermal
growth factor (EGF) (1). TGF-b was shown to
potently inhibit the proliferation of most cell types,
including epithelial cells, endothelial cells, hemato-
poietic cells, and lymphocytes, and is widely known as
a tumor suppressor. Studies investigating TGF-b
signaling have revealed that perturbations of the
TGF-b signaling pathway, such as mutations of
TGF-b receptors or Smad proteins, lead to cancer
progression and are related to poor prognosis of
certain types of cancer. However, recent ﬁndings
have shown that cancer cells become resistant to
the growth inhibitory activity of TGF-b and that
TGF-b facilitates invasion and metastasis of these
cells both in vitro and in vivo.
Accumulating evidence has revealed that TGF-b
plays a bidirectional role in cancer progression (2,3).
TGF-b acts as a tumor suppressor by inhibiting cell
growth through suppressing c-Myc expression and
stimulating certain cyclin-dependent kinase inhi-
bitors, including p21
WAF1 and p15
Ink4b, and by
inducing cellular apoptosis through inducing DAP
kinase, GADD45b, and Bim (4). Conversely,
TGF-b functions as a tumor-promoting factor by
stimulating extracellular matrix deposition and tissue
ﬁbrosis, perturbing immune and inﬂammatory func-
tion, stimulating angiogenesis, and promoting
epithelial-mesenchymal transition (EMT).
In this review article, we discuss the tumor-
promoting functions of TGF-b, particularly on
EMT, on the basis of recent ﬁndings in our
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some cancer-initiating cells and discuss how inhibi-
tion of TGF-b signaling can be used for treating
different types of cancer.
TGF-b family signaling
TGF-b binds to two different serine/threonine kinase
receptors, TbRII and TbRI (5). Betaglycan, also
known as the TGF-b type III receptor, facilitates
binding of TGF-b (particularly TGF-b2 among the
three isoforms of TGF-b)t oT bRII. TbRII activates
TbRI through phosphorylation of the Gly-Ser-rich
(GS) domain of TbRI, which in turn phosphorylates
and activates Smad2 and Smad3, receptor-regulated
Smads (R-Smads) speciﬁc for TGF-b and activin
signaling (Figure 1). Bone morphogenetic proteins
(BMPs) activate another set of R-Smads, including
Smad1, Smad5, and Smad8 (6). Activated Smad2
and Smad3 form complexes with Smad4, common
partner Smad (co-Smad), and translocate into the
nucleus. R-Smad/co-Smad complexes associate
with various transcription factors (AP-2, Ets, and
HNF-4a (7–9)) and transcriptional co-activators
(p300, CBP, and GCN5) or co-repressors (p107,
Ski, and SnoN) in the nucleus and regulate transcrip-
tion of a wide spectrum of TGF-b target genes.
Smad7, an inhibitory Smad (I-Smad), represses
TGF-b signaling through multiple mechanisms;
among these mechanisms, binding to activated type
I receptors and competition with R-Smads for recep-
tor binding play a major role in regulation of TGF-b
signaling (10). c-Ski (also known as SKI) and the
related SnoN (also known as SKIL) bind directly to
Smad2/3 and Smad4 and function as transcriptional
co-repressors by recruiting histone deacetylases
and competing for binding with p300/CBP.
C-Ski also disrupts formation of the R-Smads and
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Figure 1. Schematic representation of TGF-b signal transduction pathways. TGF-b transduces signals through two different types of serine/
threonine (and tyrosine) kinase receptors,termed TbRI and TbRII. Upon TGF-b binding, TbRI and TbRII form heterotetrameric complexes,
and TbRII kinase transphosphorylates the juxtamembrane portion (GS domain) of the cytoplasmic region of TbRI. Phosphorylated TbRI
transmits intracellular signaling through R-Smad phosphorylation. Smad2 and Smad3 are R-Smads phosphorylated by TbRI kinase and form
heteromeric complexes with Smad4 (co-Smad). Smad complexes translocate into the nucleus and act as transcriptional regulators of target
genes by interacting with other transcription factors and transcriptional regulators. Smad7 (I-Smad), which lacks the typical MH1 domain,
interferes with the activation of R-Smads by interacting with TbRI and competitively prevents R-Smads from being phosphorylated by TbRI.
TGF-b activates other intracellular signaling pathways in addition to Smads in order to regulate a wide array of cellular functions. These non-
Smad pathways are activated by TGF-b receptors through phosphorylation or direct interaction.
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addition to its involvement in Smad signaling path-
ways, TGF-b activates various non-Smad signaling
pathways, including ERK, JNK, and p38 MAP
kinases, phosphatidylinositol-3 kinase (PI3K)-Akt,
and small GTPase pathways (12). TbRI functions
as a dual-speciﬁcity kinase (tyrosine and serine/
threonine kinase) and phosphorylates ShcA on tyro-
sine and serine residues to activate the MAP kinase
pathway (13).
Induction of EMT
EMT is a differentiation switch through which epi-
thelial cells differentiate into mesenchymal cells, and
it occurs in the process of tissue morphogenesis
during development, wound repair, and cancer pro-
gression in adult tissues (14,15). An early event of
EMT includes disruption of tight junctions connect-
ing epithelial cells and delocalization of tight junction
proteins, such as ZO-1, claudin-1, and occludin.
Early events of EMT also include disruption of
adherence junctions, which contain E-cadherin and
b-catenin, and reorganization of the actin cyto-
skeleton. Epithelial cells lose cell polarity and show
spindle-like morphology with expression of various
mesenchymal markers, including N-cadherin, ﬁbro-
nectin, and a-smooth muscle actin (a-SMA). Cell
motility and invasive properties are enhanced in
resulting mesenchymal cells.
EMT can be classiﬁed into three subtypes (16).
Type 1 EMT occurs during development and
includes the mesenchymal transition of primitive epi-
thelial cells during gastrulation, generation of migrat-
ing neural crest cells from neuroepithelial cells, and
formation of endocardial cushion tissue from cardiac
endothelial cells. Type 2 EMT includes the transition
of secondary epithelial (and endothelial) cells to tissue
ﬁbroblasts, which can be observed during the pro-
cesses of wound healing, regeneration, and ﬁbrosis in
adult tissues. Type 3 EMT also occurs in adult tissues
and involves the mesenchymal transition of epithelial
carcinoma cells, leading to generation of metastatic
tumor cells.
TGF-b is well known to induce EMT in various
epithelial cells, including normal mouse epithelial
NMuMG cells and A549 lung adenocarcinoma cells
(17). Many transcription factors, including the two-
handed zinc-ﬁnger factors dEF1 (also known as
ZEB1) and SIP1 (ZEB2), the zinc-ﬁnger factors Snail
(also known as SNAI1) and Slug (SNAI2), and the
basic helix-loop-helix (bHLH) factors Twist and
E12/E47, are induced by TGF-b signaling in a
Smad-dependent fashion and play critical roles in
EMT induction. Additionally, non-Smad signaling
pathways activated by TGF-b and cross-talk with
other signaling pathways, including ﬁbroblast growth
factor (FGF) and tumor necrosis factor-a (TNF-a)
signaling, play important roles in EMT promotion.
Induction of EMT in tumor stromal cells by
TGF-b
Epithelial cells in the tumor stroma undergo EMT
(type 2 EMT) and play a critical role in cancer
progression. We cocultured NMuMG cells with
mouse mammary tumor JygMC(A) cells and found
that NMuMG cells that have undergone EMT
express a-SMA (18). The effect of the JygMC(A)
cells was abolished by treatment with the TbRI inhib-
itor SB431542. Interestingly, when NMuMG cells
were cocultured with the mouse mammary tumor cell
line 4T1, NMuMG cells underwent EMT and pro-
duced mesenchymal cells with an activated ﬁbroblas-
tic phenotype, which lacked a-SMA expression.
4T1 cells produced TGF-b1 at a level comparable
to that produced by JygMC(A) cells. When 4T1 cells
were treated with FGF receptor 1 (FGFR1) inhibitor
SU5402, a-SMA-positive NMuMG cells were
detected, indicating that the loss of a-SMA expres-
sion is due to FGF(s) secreted from 4T1 cells. We
have shown that treatment of NMuMG cells with
TGF-b and FGF-2 prevents the production of mes-
enchymal cells expressing a-SMA and calponin by
activating the MEK-ERK pathway. Interestingly,
NMuMG cells that have undergone EMT following
treatment with TGF-b and FGF-2 exhibit drastic
morphological changes with marked actin reorgani-
zation, enhanced cell migration, and increased pro-
duction of matrix metalloproteinases (MMPs),
including MMP-9. Moreover, NMuMG cells treated
with TGF-b and FGF-2 enhanced the invasion of
cocultured breast cancer cells into collagen gels
in vitro. Thus, TGF-b and FGF-2 co-operate with
each other to produce ‘activated’ ﬁbroblasts in the
tumor microenvironment, and activated ﬁbroblasts
may in turn secrete substances such as MMPs to
induce invasion and metastasis of adjacent cancer
cells (Figure 2).
During EMT progression, TGF-b induces isoform
switching of FGFRs. Of the 22 FGFs (19), epithelial
cells respond to speciﬁc FGFs, including FGF-7 (also
known as keratinocyte growth factor (KGF)), but not
to FGF-2 (basic FGF) or FGF-4. However, cells that
have undergone EMT become responsive to FGF-2
and FGF-4, but not to FGF-7 (18). We have shown
that TGF-b-mediated EMT induces isoform switch-
ing of FGFRs through alternative splicing, following
which expression of the IIIb isoform of FGFR
decreased and that of the IIIc isoform increased.
Tumor-promoting functions of TGF-b in cancer 145Exon array analysis showed that TGF-b alters a broad
spectrum of splicing patterns by reducing the expres-
sion of epithelial splicing regulatory proteins (ESRPs)
1 and 2 (20). Warzecha et al. (21) recently reported
that the ESRP-regulated splicing pathway is abro-
gated during EMT. We found that repression of
the expression of ESRPs by TGF-b is mediated by
up-regulation of the dEF1 family proteins dEF1 and
SIP1, which suppress the transcription of ESRP(s) by
binding to the ESRP promoter(s). Interestingly, the
expression proﬁles of ESRPs were reciprocally corre-
lated with those of dEF1 and SIP1 in human breast
cancer cell lines as well as in tumor specimens.
In addition to FGFRs, TGF-b induces alternative
splicing of CD44, Mena, and CTNND1 (also known
as d-catenin or p120 catenin), which are reportedly
involved in cancer progression. We have also shown
that over-expression of ESRPs attenuates TGF-
b-induced EMT and restores the expression of
E-cadherin and some other epithelial phenotypes.
Thus, ESRPs are downstream targets of TGF-b
and serve as antagonists to EMT by regulating
alternative splicing of speciﬁc genes involved in
TGF-b-induced EMT.
Induction of EMT in cancer cells
EMT is observed in some transformed epithelial cells
(type 3 EMT) to facilitate their invasive and meta-
static properties. Type 3 EMT can be regulated by
speciﬁc oncogenic and anti-oncogenic signals. We
have shown that a zinc-ﬁnger transcription factor
Snail is induced by TGF-b in pancreatic cancer
Panc1 cells and plays a key role in EMT progression
(22). Panc1 cells express active K-ras, and we found
that induction of Snail by TGF-b is dependent on
oncogenic Ras signals. Snail was strongly induced by
TGF-b in Panc1 cells, but knock-down of Ras in
Panc1 cells abolished Snail induction by TGF-b.
Consequently, TGF-b failed to efﬁciently induce
EMT in Panc1 cells in the absence of active Ras
signaling. Exogenous expression of constitutively
active Ras into HeLa cells resulted in marked induc-
tion of Snail by TGF-b, while induction of other
direct targets of TGF-b, including Smad7 and
PAI-1, was not enhanced by Ras signaling. MAP
kinases have been reported to phosphorylate the
linker region of Smad2 and Smad3, which both
positively and negatively regulates TGF-b signaling
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Figure 2. Schematic representation of EMT induction by TGF-b and FGF-2. ‘Epithelial cells’ differentiate into ‘ﬁbroblastic cells’ through
EMT induced by TGF-b and further differentiate into a-SMA-positive ‘myoﬁbroblastic cells’ through epithelial-myoﬁbroblastic transition
(EMyoT). When FGF-2 is present in this process, FGF-2 induces differentiation of epithelial cells to ‘activated ﬁbroblastic cells’.
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required for induction of Snail by TGF-b, and it is
currently unknown which downstream signals of Ras
co-operate with TGF-b signaling (22).
Thyroid transcription factor-1 (TTF-1, the protein
product of the NKX2.1 gene) is expressed in normal
lung tissues and acts as a master regulator of lung
morphogenesis (24). TTF-1 is primarily expressed in
type II pneumocytes and Clara cells and frequently
expressed in lung cancer cells, including lung adeno-
carcinoma cells. Although the TTF1 gene is ampliﬁed
in some lung adenocarcinoma cells and may function
as an oncogene (25), loss of TTF-1 expression is
reportedly associated with poor prognosis of lung
carcinoma. Recently, Winslow et al. (26) reported
that TTF-1 controls differentiation of lung carcinoma
cells and limits their metastatic potential in mice with
active K-Ras and inactive p53. Interestingly, we found
that TTF-1 functions as a tumor-suppressor during
EMT induction. TTF-1 is highly expressed in certain
types of lung adenocarcinoma cell lines, including
H441 cells and LC-2/ad cells, but not in A549 cells
(27). A549 cells show a spindle-like phenotype and
grow rapidly, while H441 cells show tight cell–cell
junctions with cobblestone-like morphology and grow
much more slowly than A549 cells. A549 cells express
low levels of TTF-1 and E-cadherin, while H441 cells
express high levels of TTF-1 and E-cadherin. We
have further shown that exogenous expression of
TTF-1 in A549 cells inhibits TGF-b-induced
EMT, decreases MMP-2 activity, cell migration,
and cellular invasive capacity, and restores the epi-
thelial phenotype through high E-cadherin expres-
sion. Conversely, TGF-b induces the expression of
Snail and Slug in A549 cells, and silencing of
TTF-1 in H441 cells enhances TGF-b-mediated
EMT. TTF-1 has been reported to interact physically
with Smad3 (28) and may inhibit Smad3 function.
We have also shown that TGF-b down-regulates
TTF-1 expression in A549 cells and that TTF-1
inhibits the expression of TGF-b2, which is expressed
in epithelial cells at the tip of the distal airway during
lung morphogenesis. Thus, TTF-1 may exert a
tumor-suppressive effect through antagonizing the
effect of TGF-b. These ﬁndings indicate a function-
ally inverse relationship between TTF-1 and TGF-b
signaling in the progression of lung adenocarcinoma
through regulation of EMT.
TGF-b signaling in vascular tissues and
angiogenesis
New blood vessel formation in tumor tissues (tumor
angiogenesis) is essential for the growth and metas-
tasis of tumor cells. Although TGF-b potently inhibits
the growth of endothelial cells in vitro, it functions
as a pro-angiogenic factor and stimulates angio-
genesis in vivo. Increased expression of TGF-b is
correlated to increased vascular density in some types
of tumors.
For induction of tumor angiogenesis, TGF-b
induces the expression of angiogenic factors, includ-
ing connective tissue growth factor (CTGF) and
vascular endothelial growth factor (VEGF) (29).
Additionally, TGF-b stimulates the synthesis of
MMP-2 and MMP-9 and down-regulates the expres-
sion of tissue inhibitors of metalloproteinase (TIMPs)
in tumor tissues. Increased MMP activity leads to
stimulation of migration and invasion of vascular
endothelial cells, resulting in accelerated tumor
angiogenesis.
However, TGF-b suppresses angiogenesis in cer-
tain types of tumors through reduced expression of
some angiogenic factors or increased expression of
angiogenic inhibitors. In diffuse-type gastric carci-
noma, TGF-b induces the production of some angio-
genic inhibitors, including thrombospondin-1 and
TIMP-2, and perturbations of TGF-b signaling
may thus lead to induction of angiogenesis and tumor
growth in vivo (30,31).
In addition to induction of tumor angiogenesis,
TGF-b acts on vascular endothelial cells and may
disrupt cell–cell junctions and support the coloniza-
tion of tumor cells to establish metastasis. Using
endothelial cells derived from mouse embryonic
stem (ES) cells, we showed that TGF-b suppresses
the expression of claudin-5 and disrupts sheet
formation in vitro (32). We also showed that
TGF-b induces differentiation of certain endothelial
cells into mesenchymal cells, resulting in the loss of
tight cell–cell contacts in vitro (33). Moreover,
through disruption of endothelial cell–cell junctions
by inducing angiopoietin-like 4 (Angptl4) expression,
TGF-b has been shown to increase the permeability of
blood vessels and stimulate the trans-endothelial
movement of cancer cells (34).
Acceleration of cancer metastasis by TGF-b
signaling
TGF-b facilitates metastasis of certain types of cancer
in advanced stages, including breast cancer (35).
Inhibition of TGF-b signaling may thus be a potential
strategy for preventing metastasis of advanced can-
cers. Though not discussed in detail in this review,
TGF-b regulates tumor development by regulating
immune functions (36,37). Wakeﬁeld and colleagues
reported that inhibition of TGF-b function prevents
the progression of breast cancer by enhancing various
immune functions (38).
Tumor-promoting functions of TGF-b in cancer 147We have shown that Smad7, an I-Smad that inhi-
bits TGF-b and BMP signaling, efﬁciently inhibits
lung and liver metastasis of mouse breast cancer
JygMC(A) cells (39). We subcutaneously inoculated
JygMC(A) cells, which spontaneously metastasize to
the lung, liver, and other organs in 3 to 4 weeks, in
nude mice. Ten days after subcutaneous inoculation,
adenoviruses containing Smad7 or LacZ were intra-
venously administered to the mice once weekly. Mice
bearing JygMC(A) tumors and treated with LacZ
adenovirus developed numerous metastases to the
lung and liver, and all mice died by 50 days (median
survival time, 41 days) after inoculation of JygMC(A)
cells. In contrast, mice treated with Smad7 adenovi-
rus showed a signiﬁcant decrease in metastases of
tumors in both the lung and liver, and the median
survival time of Smad7-treated mice was 55 days.
JygMC(A) cells treated with Smad7 showed increased
expression of components involved in adherence and
tight junctions, including E-cadherin, and decreased
expression of mesenchymal markers, including
N-cadherin. Smad7 also inhibited the migration
and invasion of cells, indicating that Smad7 leads
to prevention of the EMT process. Interestingly,
Smad6, which preferentially inhibits BMP signaling,
failed to show signiﬁcant effects on the metastasis of
JygMC(A) cells in nude mice, whereas c-Ski adeno-
virus showed effects similar to Smad7. Thus, inhibit-
ing TGF-b signaling using Smad7 or c-Ski prevents
the EMT process and eventually inhibits lung and
liver metastasis of JygMC(A) cells (Figure 3).
In addition to preventing EMT, TGF-b appears to
inhibit metastasis of JygMC(A) cells by some other
mechanisms. Although TGF-b induces apoptosis of
many different types of cells by inducing speciﬁc
genes, it stimulates survival of certain types of cells
in a context-dependent manner through activation of
the PI3K-Akt signaling pathway. We have identiﬁed
Dec1 (differentially expressed in chondrocytes 1, also
known as SHARP2 and Stra13) as a downstream
target of TGF-b–Smad signaling by DNA microarray
analysis (40). Dec1 is a bHLH transcription factor,
which is widely expressed in many tissues and over-
expressed in certain types of cancer cells. Dec1 pre-
vented the apoptosis of JygMC(A) as wellas 4T1 cells,
and a dominant-negative mutant of Dec1 suppressed
lung and liver metastases of JygMC(A) cells in nude
mice (Figure 3). Dec1 has been reported to induce the
expression of an anti-apoptotic protein, survivin, in
certain types of cells (41); however, we failed to show
induction of survivin by TGF-b in JygMC(A) cells.
Mechanisms of Dec1 induction of cell survival in
JygMC(A) cells should be examined in the future.
We also found that inhibiting endogenous TGF-b
signaling by a TbRI inhibitor, SB431542, induces the
expression of the BH3-only protein, Bim (also known
as Bcl2-like 11), in JygMC(A) and stimulates apopto-
sis in these cells (42). We showed that suppression of
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Figure 3. Mechanisms of TGF-b action on prevention of breast cancer metastasis using JygMC(A) cells. Endogenously activated autocrine
loop of TGF-b regulates the expression of E-cadherin and N-cadherin by inducing EMT in JygMC(A) cells. Autocrine TGF-b also regulates
the expression of various transcription factors, including Dec1 and Foxc1, and promotes the survival. Negative regulators of TGF-b signaling
(Smad7, c-Ski, or TGF-b inhibitors) block these pathways and inhibit metastasis of JygMC(A) cells.
148 K. Miyazono et al.Bim expression by TGF-b is mediated by repression
of a FOX family transcription factor, Foxc1, in
JygMC(A) cells, thus suggesting an important role
of the TGF-b–Foxc1–Bim axis in the survival of
certain types of cells. Further studies are needed to
determine whether the TGF-b–Foxc1–Bim axis is
involved in lung and liver metastases of this type of
cancer (Figure 3).
TGF-b also plays critical roles in bone metastasis,
during which functional interaction between cancer
cells and the bone microenvironment is important.
In-vivo experimental models using intracardiac injec-
tion of cancer cells have been widely used to study the
mechanisms of bone metastasis. Several studies
revealed that TGF-b and its target molecules, such
as parathyroid hormone-related protein (PTHrP)
and interleukin-11 (IL-11), play critical roles in the
development of bone metastasis of breast cancers
(29,43), which occurs in a Smad-dependent fashion
(44). PTHrP stimulates the expression of the RANK
ligand (RANKL) in osteoblasts and induces differen-
tiation of osteoclast precursors and resorption of bone.
WestudiedtheeffectsofaTbRIinhibitor,Ki26894,on
bone metastasis in the human breast cancer cell line
MDA-MB-231–5a-D (MDA-231-D), which is a
highly metastatic variant of MDA-MB-231 cells.
Ki26894 suppressed induction of PTHrP and IL-11
mRNA in MDA-231-D cells stimulated by TGF-b
(45). When MDA-231-D cells were injected into the
left ventricle of nude mice and treated with systemic
administration of Ki26894 (treatment with Ki26894
was started 1 day before tumor cell inoculation), X-ray
radiography showed that treatment with Ki26894
decreased bone metastasis of breast cancer cells and
prolonged the survival of MDA-231-D-bearing mice
compared to vehicle treatment. These ﬁndings suggest
that inhibition of TGF-b signaling may be useful for
preventingbonemetastasisofadvancedbreastcancers.
TGF-b maintains stemness of certain cancer-
initiating cells
Cancer-initiating cells show increased tumor-
initiating ability and often exhibit stem cell-like prop-
erties such as self-renewal, multipotency, and
expression of speciﬁc stem cell markers. The concept
of cancer-initiating cells reveals a new strategy of
therapy against intractable cancers, though it remains
unclear how cancer-initiating cells can be speciﬁcally
eradicated. It is important to investigate the differ-
ences between cancer-initiating cells and normal stem
cells and to identify speciﬁc molecules to target
cancer-initiating cells without affecting the function
of normal stem cells. Recent studies have also
revealed critical roles of TGF-b signaling in the
maintenance of stem cell-like properties of certain
cancer-initiating cells, including glioma-initiating
cells (GICs) (46,47), breast cancer-initiating cells
(48), and leukemia-initiating cells in chronic myeloid
leukemia (CML) (49).
Glioma cells produce TGF-b1 and TGF-b2, and
autocrine TGF-b signaling plays a pivotal role in
maintaining the stem cell-like properties and tumor-
igenic activity of GICs (46,47). GICs obtained from
patients with glioblastoma multiforme exhibit sphere-
forming ability in a self-renewal medium containing
EGF and FGF-2. Although TGF-b did not signiﬁ-
cantly affect the sphere-forming ability of GICs, a
TbRI inhibitor, SB431542, efﬁciently reduced this
ability in GICs. Moreover, SB431542 dramatically
reduced the number of CD133-expressing cells and
induced differentiation of GICs, leading to the
appearance of cells expressing neural or glial cell
markers. Analyses of TGF-b target genes using quan-
titative RT-PCR and by searching public datasets
showed that TGF-b induces expression of the Sry-
related HMG box (Sox) transcription factors
Sox2 and Sox4. We showed that Sox4 is a direct
target of Smad proteins activated by TGF-b and
that it induces the expression of Sox2, which plays
a critical role in the maintenance of GIC stemness.
We also conﬁrmed that in intracranial transplantation
assays using immunocompromised mice, GICs pre-
treated with SB431542 showed decreased lethal
potency. These results indicate that the TGF-b–
Sox4–Sox2 pathway is essential for retaining the
stemness of GICs, and inhibition of TGF-b signaling
may be a potential method for treating glioma through
targeting GICs (Figure 4).
Westermark and his colleagues (50) reported that
another Sox family protein, Sox21, is expressed in gli-
oma cells. Sox21 is an antagonizing partner of Sox2
and negatively regulates the expression of Sox2 in
glioma cells. They showed that reduction in Sox2
expressionusingSox2siRNAorSox21over-expression
reduced the cell number by inducing apoptosis.
In addition to the Sox4-Sox2 pathway, TGF-b
also induces the expression of leukemia inhibitory
factor (LIF) in a Smad-dependent fashion. LIF acti-
vates the downstream JAK-STAT pathway, leading to
increased tumorigenesis of GICs (47). Anido et al.
have shown that TGF-b inhibitors target GICs with
high levels of CD44 and Id1 and that CD44
high/
Id1
high GICs are generally localized in the perivascu-
lar niche (51).
Conclusion and perspectives
As proposed by Roberts and Wakeﬁeld (2), it is now
well known that TGF-b exhibits both positive and
Tumor-promoting functions of TGF-b in cancer 149negative effects on cancer progression. The bidirec-
tional roles of TGF-b can be observed at the molec-
ular, cellular, and tissue levels. Although we described
the positive effects of TGF-b on maintaining the
stemness of cancer-initiating cells, TGF-b has also
been shown to decrease the number of speciﬁc
types of cancer-initiating cells, including diffuse-
type gastric carcinoma cells (52). Moreover, TGF-b
induces maintenance of stem cell-like properties of
certain breast cancer-initiating cells (48), while sup-
pression of the TGF-b pathway leads to an increase in
breast cancer-initiating cells in other types of breast
cancer cells (53), thereby suggesting that the response
to TGF-b varies depending on the type of cancer-
initiating cells.
Mani et al. (48) reported that TGF-b maintains
stem cell-like properties of certain cancer-initiating
cells through induction of EMT. They showed that
normal and transformed mammary epithelial cells
acquired stem cell-like properties with high tumori-
genic activity when EMT was induced in these cells by
TGF-b. Although we have not determined whether
the sizes of cancer-initiating cell compartments are
affected by EMT in the pancreatic carcinoma
Panc1 cells and lung adenocarcinoma A549 cells
described above, these ﬁndings suggest a functional
connection between EMT and cancer-initiating prop-
erties of certain epithelial cells.
Recent ﬁndings based on genome-wide analyses of
Smad-binding sites in some types of cells, which were
performed using ChIP-sequencing analyses, revealed
that the binding proﬁles of Smads differ remarkably
depending on the cell types and are affected by
interaction with transcription factors expressed in
each cell type and by cell-speciﬁc differences in base-
line chromatin accessibility patterns (7,9,54). It is
thus possible that the response of cells to TGF-b
may be differentially affected by coexisting transcrip-
tion factors and chromatin assembly patterns. Further
studies examining global gene expression proﬁles and
genome-wide maps of protein binding sites or epige-
netic marks using high-throughput sequencing may
be valuable for elucidating the mechanisms of differ-
ential cellular responsiveness to TGF-b.
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